1. Scrip
  2. >>R&D

Parexel Execs On How To Adapt Clinical Studies Amid The Pandemic

Decentralized, Remote Approaches Adopted

 
• By Anju Ghangurde

Parexel executives tell Scrip about the company’s efforts in tandem with sponsors to navigate the challenging clinical research environment amid COVID-19. A renewed interest for decentralized trials or hybrid approaches and the use of remote monitoring and telehealth visits to keep studies moving are some of the key initiatives.

Clinical trial
Clinical Research Segment Tackles Challenges Amid COVID-19 • Source: Shutterstock

The clinical research segment, like many other businesses, is dealing with a complex, new normal as the world struggles to tackle the coronavirus pandemic.

Parexel executives Peyton Howell, chief commercial and strategy officer, and Sanjay Vyas, senior vice-president, India country head and head of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 
• By Sushmita Panda

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.